Nuclear FAK Protects Ovarian Cancer Cells from Cisplatin Stress
Author Information
Author(s): Yichi Zhang, Marjaana Ojalill, Antonia Boyer, Xiao Lei Chen, Elise Tahon, Gaëtan Thivolle Lioux, Marvin Xia, Maryam Abbas, Halime Meryem Soylu, Douglas B. Flieder, Denise C. Connolly, Alfredo A. Molinolo, Michael T. McHale, Dwayne G. Stupack, David D. Schlaepfer
Primary Institution: Moores Cancer Center, University of California, San Diego
Hypothesis
Does nuclear localization of FAK contribute to cisplatin resistance in high-grade serous ovarian cancer?
Conclusion
Nuclear FAK limits cisplatin-induced cell death by regulating MKP1 levels and preventing ERK activation.
Supporting Evidence
- FAK is tyrosine-phosphorylated and nuclear-localized in tumors of patients with HGSOC.
- FAK nuclear localization sequence mutational inactivation sensitizes tumor cells to cisplatin.
- MKP1 levels are significantly elevated in wild-type FAK compared to FAK-NLS− ovarian tumor cells.
Takeaway
This study shows that a protein called FAK helps ovarian cancer cells survive chemotherapy by staying in the nucleus and controlling other proteins.
Methodology
The study involved cell line experiments, immunoblotting, and analysis of patient tumor samples to assess FAK localization and activity.
Potential Biases
Potential bias in patient sample selection and interpretation of immunohistochemistry results.
Limitations
The study primarily focuses on in vitro and murine models, which may not fully replicate human responses.
Participant Demographics
Patients with high-grade serous ovarian cancer who underwent neoadjuvant chemotherapy.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website